HK Stock Market Move | VISEN PHARMA-B (02561) closes up more than 4%, the company reaches multiple cooperation agreements at the Import Expo, showcasing two global innovative drugs.

VISEN PHARMA-B (02561) rose more than 4% by the end of the day's trading, closing at 4.05% higher at HK$34.98 with a turnover of HK$96.64 million. On the news front, during the 8th China International Import Expo on November 6th, innovative pharmaceutical company Visen Pharma in the field of endocrinology reached a strategic cooperation with Tofflon Science and Technology Group, a leading domestic pharmaceutical equipment company, on the technology of dual-chamber lyophilized preparations. They also signed an industrial synergy agreement with the Lingang New Area Management Committee and the Lingang Group Trade Platform, marking further progress in their strategic practice of "global innovation, accelerated in China". It is worth noting that Visen Pharma made its first appearance as an exhibitor at the 8th China International Import Expo this year, showcasing two globally innovative drugs. Among them, Paropeptide Leptopyramide is the world's first and only hormone replacement therapy drug for adult hypoparathyroidism (HP), and the potential best-in-class drug Longpei Growth Hormone is also making its debut simultaneously.